Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | PDE2A | O00408 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.57 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.57 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174996 | 0.88 | ALDH1A1 (0.56) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL3070663 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL4532457 | 0.84 | ALDH1A1 (0.55) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL4532764 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL4513265 | 0.84 | HSD17B10 (0.56) | ALDH1A1TDP1CYP3A4PDE2APDE5A | |
| SCHEMBL24723083 | 0.84 | ALDH1A1 (0.44) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL10417384 | 0.84 | L3MBTL1 (0.55) | ALDH1A1TSHRTDP1L3MBTL1MAPT | |
| SCHEMBL10175659 | 0.83 | ALDH1A1 (0.64) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL14768876 | 0.83 | ALDH1A1 (0.64) | ALDH1A1TSHRTDP1CYP3A4PDE2A | |
| SCHEMBL4524927 | 0.81 | TDP1 (0.57) | ALDH1A1TDP1CYP3A4CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| CN-107531645-A | The inhibitor of gangrenosum acne apoptosis | 催化剂治疗私人有限公司 | 2018-01-02 | — | — | CN | disclosed |
| WO-2016127213-A1 | INHIBITORS OF NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2016-08-18 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | ALDH1A1 2632/4885TSHR 22/4885TDP1 3651/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | ALDH1A1 2449/4885TSHR 2524/4885TDP1 2226/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | ALDH1A1 887/4885TSHR 1179/4885TDP1 1898/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | ALDH1A1 4651/4885TSHR 4108/4885TDP1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.